Boston Scientific (BSX) Receives FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
More News related to ABT
- Abbott to Present at Bank of America 38th Annual Investment Conference
- Abbott to Present at UBS 'Best of Americas' Investment Conference
- Morgan Stanley Resumes Abbott Labs (ABT) at Overweight
- Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
- Zimmer Holdings (ZMH) Acquires Abbott's Spine Business
More News related to BSX
- Notable Analyst Rating Changes 9/5: UL, MON, NAV, HOS Upgraded; ANF, TJX, AMD, NBR Downgraded
- Morgan Stanley Assumes Coverage on Boston Scientific (BSX) with an Overweight
- TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
- Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
- Boston Scientific (BSX) Announces U.S. District Court of Marshall, TX Rejects 2 Medtronic Patents
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. FDA has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System manufactured by Abbott Labs (NYSE: ABT) and distributed by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.
The PROMUS Stent expands Boston Scientific's drug-eluting stent portfolio, which includes the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System and the TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System, making Boston Scientific the only company to offer physicians the choice of two distinct drugs on separate DES platforms.
Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in various interventional medical specialties worldwide.
Related Categories
FDAStocks Mentioned
+0.44Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Congrats to BSX
Kevin Ott on Jul 2, 2008 05:46 PMThis is great news for the DES market. BSX will be the first and only for the seeable future to have two distinct platforms to finally give doctors a choice. After much debate for several years, finally a company can offer a choice without having to pressure physicians to only their product. Even though ABT also has the product under the name Xience, they still do not have the ability to offer choice. Both products have demonstrated effectiveness and BSX has a real stake in the landscape.